Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The hippo signaling pathway in pancreatic cancer

Ansari, Daniel LU ; Ohlsson, Henrik LU ; Althini, Carl ; Bauden, Monika LU orcid ; Zhou, Qimin LU orcid ; Hu, Dingyuan LU and Andersson, Roland LU (2019) In Anticancer research 39(7). p.3317-3321
Abstract

Hippo signaling is a key regulator of organ size, tissue hemostasis and regeneration. Dysregulation of the Hippo pathway has been recognized in a variety of human cancers, including pancreatic cancer. YES-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are the two major downstream effectors of the Hippo pathway. YAP and TAZ have been found to promote pancreatic tumor development and progression, even in the absence of mutant Kirsten RAS (KRAS). Pancreatic cancer is associated with an abundant stromal reaction leading to tumor growth and immune escape. It has been found that YAP and TAZ modulate behavior of pancreatic stellate cells and recruitment of tumor-associated macrophages and myeloid-derived... (More)

Hippo signaling is a key regulator of organ size, tissue hemostasis and regeneration. Dysregulation of the Hippo pathway has been recognized in a variety of human cancers, including pancreatic cancer. YES-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are the two major downstream effectors of the Hippo pathway. YAP and TAZ have been found to promote pancreatic tumor development and progression, even in the absence of mutant Kirsten RAS (KRAS). Pancreatic cancer is associated with an abundant stromal reaction leading to tumor growth and immune escape. It has been found that YAP and TAZ modulate behavior of pancreatic stellate cells and recruitment of tumor-associated macrophages and myeloid-derived suppressor cells. Moreover, YAP and TAZ are associated with chemoresistance and poor prognosis in pancreatic cancer. This review dissects the role of Hippo signaling in pancreatic cancer, focusing on molecular mechanisms and prospects for future intervention.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Chemoresistance, EMT, Hippo pathway, Immunomodulation, Pancreatic Cancer, Review, Stroma, TAZ, Treatment, Tumor progression, YAP
in
Anticancer research
volume
39
issue
7
pages
5 pages
publisher
International Institute of Cancer Research
external identifiers
  • scopus:85068253186
  • pmid:31262852
ISSN
0250-7005
DOI
10.21873/anticanres.13474
language
English
LU publication?
yes
id
00bf0b24-b9fe-4e3f-9e6b-5a56b6e86fca
date added to LUP
2019-07-11 09:49:02
date last changed
2024-05-28 20:52:08
@article{00bf0b24-b9fe-4e3f-9e6b-5a56b6e86fca,
  abstract     = {{<p>Hippo signaling is a key regulator of organ size, tissue hemostasis and regeneration. Dysregulation of the Hippo pathway has been recognized in a variety of human cancers, including pancreatic cancer. YES-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are the two major downstream effectors of the Hippo pathway. YAP and TAZ have been found to promote pancreatic tumor development and progression, even in the absence of mutant Kirsten RAS (KRAS). Pancreatic cancer is associated with an abundant stromal reaction leading to tumor growth and immune escape. It has been found that YAP and TAZ modulate behavior of pancreatic stellate cells and recruitment of tumor-associated macrophages and myeloid-derived suppressor cells. Moreover, YAP and TAZ are associated with chemoresistance and poor prognosis in pancreatic cancer. This review dissects the role of Hippo signaling in pancreatic cancer, focusing on molecular mechanisms and prospects for future intervention.</p>}},
  author       = {{Ansari, Daniel and Ohlsson, Henrik and Althini, Carl and Bauden, Monika and Zhou, Qimin and Hu, Dingyuan and Andersson, Roland}},
  issn         = {{0250-7005}},
  keywords     = {{Chemoresistance; EMT; Hippo pathway; Immunomodulation; Pancreatic Cancer; Review; Stroma; TAZ; Treatment; Tumor progression; YAP}},
  language     = {{eng}},
  number       = {{7}},
  pages        = {{3317--3321}},
  publisher    = {{International Institute of Cancer Research}},
  series       = {{Anticancer research}},
  title        = {{The hippo signaling pathway in pancreatic cancer}},
  url          = {{http://dx.doi.org/10.21873/anticanres.13474}},
  doi          = {{10.21873/anticanres.13474}},
  volume       = {{39}},
  year         = {{2019}},
}